4570
Immuno-Biological Laboratories Co.,Ltd.
免疫生物研究所
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Mar 2022
647,576
Mar 2023
794,621
Mar 2024
816,701
Mar 2025
969,533
Mar 2026
1,004,987
Operating profit(thousand JPY)
Mar 2022
-122,219
Mar 2023
58,373
Mar 2024
104,299
Mar 2025
209,345
Mar 2026
281,277
Operating profit margin(%)
Mar 2022
-18.87
Mar 2023
7.35
Mar 2024
12.77
Mar 2025
21.59
Mar 2026
27.99
Profit before tax(thousand JPY)
Mar 2022
-250,142
Mar 2023
-280,611
Mar 2024
124,644
Mar 2025
209,861
Mar 2026
300,562
Profit(thousand JPY)
Mar 2022
-258,767
Mar 2023
-289,731
Mar 2024
186,694
Mar 2025
249,047
Mar 2026
329,015
Total assets(thousand JPY)
Mar 2022
1,705,338
Mar 2023
1,434,337
Mar 2024
1,618,582
Mar 2025
1,845,390
Mar 2026
2,155,121
Cash and cash equivalents(thousand JPY)
Mar 2022
449,184
Mar 2023
561,997
Mar 2024
674,969
Mar 2025
770,563
Mar 2026
928,257
Cash flows from operating activities(thousand JPY)
Mar 2022
-93,204
Mar 2023
26,458
Mar 2024
133,775
Mar 2025
183,495
Mar 2026
301,093
Cash flows from investing activities(thousand JPY)
Mar 2022
-155,629
Mar 2023
30,036
Mar 2024
-24,496
Mar 2025
-53,660
Mar 2026
-116,463
Cash flows from financing activities(thousand JPY)
Mar 2022
143,998
Mar 2023
991
Mar 2024
991
Mar 2025
-31,755
Mar 2026
-27,136
Return on equity(%)
Mar 2022
-
Mar 2023
-
Mar 2024
15.9
Mar 2025
17.9
Mar 2026
19.6
Equity ratio(%)
Mar 2022
80.2
Mar 2023
75.2
Mar 2024
78.2
Mar 2025
82.1
Mar 2026
85.5
Earnings per share(JPY per share)
Mar 2022
-27.78
Mar 2023
-31.1
Mar 2024
20.05
Mar 2025
26.74
Mar 2026
35.33
Net assets per share(JPY per share)
Mar 2022
146.92
Mar 2023
115.81
Mar 2024
135.85
Mar 2025
162.6
Mar 2026
197.93
Dividend per share(JPY per share)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
6
Payout ratio(%)
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Mar 2026
16.98
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.